Published in final edited form as:

Annu Rev Nutr. 2014 ; 34: 237–260. doi:10.1146/annurev-nutr-071812-161201.

Incretins and Amylin: Neuroendocrine Communication between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose

Matthew R. Hayes^{1,*}, Elizabeth G. Mietlicki-Baase¹, Scott E. Kanoski³, and Bart C. De Jonghe^{2,*}

¹Translational Neuroscience Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

²Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA

³Department of Biological Sciences, University of Southern California, Los Angeles, CA

Abstract

Arguably the most fundamental physiological systems for all eukaryotic life are those governing energy balance. Without sufficient energy, an individual is unable to survive and reproduce. Thus, an ever-growing appreciation is that mammalian physiology developed a redundant set of neuroendocrine signals that regulate energy intake and expenditure, which maintains sufficient circulating energy, predominantly in the form of glucose, to ensure that energy needs are met throughout the body. This orchestrated control requires cross-talk between the gastrointestinal tract which senses the incoming meal, the pancreas which produces glycemic counterregulatory hormones, and the brain which controls autonomic and behavioral processes regulating energy balance. Therefore, this review highlights the physiological, pharmacological, and pathophysiological effects of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), as well as the pancreatic hormone amylin, on energy balance and glycemic control.

Keywords

GLP-1; GIP; IAPP; obesity; diabetes; vagus nerve; blood glucose

Introduction

As Type II diabetes mellitus (T2DM) and obesity rates continue to reach epidemic proportions (29; 52; 179), driving health and economic costs higher (50; 51), the need to find safe, effective, and economically achievable therapies for the treatment of these diseases is ever increasing. At the most fundamental level, T2DM is a disease characterized by a derangement in insulin receptor signaling and the resulting metabolic consequences of

* Address correspondence to: Matthew R. Hayes, Ph.D., hayesmr@mail.med.upenn.edu, T: 215-573-6070, F: 215-898-9439. Bart C. De Jonghe, Ph.D., bartd@nursing.upenn.edu, T: 215-898-4901, F: 215-573-3859.

chronic hyperglycemia, while obesity represents the long-term physiological consequence of chronic overconsumption of energy in comparison to energy expended. Despite our ever-growing understanding of the environmental, anatomical, physiological, molecular, neuronal, and behavioral mechanisms that contribute to the etiology and pathophysiology of obesity/T2DM, it is clear that we have limited therapeutic options for either disease and the management of T2DM requires lifelong treatment with several classes of pharmaceuticals (45; 165). Thus, more progress is required to identify novel physiologically-relevant targets to: [1] alleviate the derangements in insulin receptor signaling for the treatment of T2DM, and [2] reduce energy intake and/or increase energy expenditure for the treatment of obesity. For these reasons, attention has been devoted to the investigation of incretin hormones like glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), as well as non-insulin pancreatic β -cell-derived hormones like amylin for the treatment of T2DM and obesity, as pharmacological manipulation of these neuroendocrine systems offers promising therapeutic potential for both diseases. This review therefore focuses on the physiological and pathophysiological neuroendocrine mechanisms mediating the glycemic- and food intake-suppressive effects of amylin, GLP-1, and GIP (see Figure 1 for an illustrative summary). Importantly, this review also highlights gaps in knowledge that may offer potential advances for improved therapeutics targeting each of these systems for the treatment of T2DM and obesity.

I. Incretin- and amylin-mediated signaling in blood glucose regulation

An incretin factor is a hormone that is secreted from the intestine (also termed insulinotropic gut peptide) in response to nutrient ingestion and elicits the secretion of insulin from the pancreatic β -cells to lower blood glucose levels postprandially [see (8; 74) for review]. Accordingly, oral glucose administration will lead to a greater increase in plasma insulin levels when compared with the same amount of glucose given intravenously (48; 114). Thus, the incretin effect refers to the increase in the amount of insulin secreted from pancreatic β -cells following oral vs. intravenous glucose administration, and is estimated to account for approximately 50% of the total insulin secreted after oral glucose administration. The incretin effect is largely mediated by the neuroendocrine actions of two insulinotropic gut peptides, GLP-1 and GIP, that are secreted from enteroendocrine “L” and “K” cells, respectively, of the intestine following nutrient entry into the GI tract (see (67; 74) for review). Interestingly, the physiological and pharmacological effects mediated by GIP and GLP-1 ligands are not restricted to glycemic regulation, nor are they entirely due to direct activation of receptors expressed on pancreatic β -cells. Instead, the relevant GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) populations mediating the physiological responses of these hormones are still being heavily explored. In the case of GLP-1, the biological processes regulated by this neuroendocrine system are abundant and include: blood glucose regulation, regulation of gastric emptying, visceral stress, cardiovascular and thermogenic effects. Importantly, GLP-1 also plays a critical role in the control of food intake and energy balance. Sections within this review will provide a brief overview of GIP and GLP-1 physiology with special attention devoted to the endocrine, neuroanatomical, and behavioral mechanisms mediating the physiological effects of these incretin factors.

The pancreatic β -cells also produce amylin (a.k.a. islet amyloid polypeptide; IAPP), a 37 amino acid peptide that is co-secreted with insulin and also plays a role in the regulation of blood glucose and other physiological functions (104; 139; 159). Amylin's secretion is also modulated in part by the presence of nutrients in the GI tract, however unlike incretin hormones, amylin's ability to modulate glycemic control is not thought to be a result of potentiated insulin release. Rather, the prevailing view is that amylin receptor activation reduces blood glucose by delaying gastric emptying, suppressing food intake, and inhibiting meal-related glucagon secretion [see (105; 157; 158) for review]. Like the incretin hormones, these effects by amylin require distributed sites of action that necessitate activation of amylin receptors in the CNS. Recent advances in amylin physiology in relation to food intake and energy balance are discussed in sections below.

II. Systemic GLP-1 regulation of blood glucose and energy intake

II.A. Vagal-dependent mediation of glycemic responses by systemic GLP-1

Within the periphery, there are three distinct populations of GLP-1Rs relevant to glycemic control, and include GLP-1R expressed on: 1) pancreatic β -cells, 2) vagal afferent fibers innervating the GI tract, and 3) vagal afferent fibers innervating the hepatoportal bed [see (67; 74) for review]. The amount of endogenous post-prandial GLP-1 released from intestinal L-cells in humans is correlated with the size of the meal. This is an important concept when considering the relevant GLP-1R population(s) within the periphery that may respond to secreted GLP-1 to control for blood glucose utilization under both normal physiological conditions, as well as during pathophysiological conditions resulting from gastric bypass and/or treatment with GLP-1-based pharmaceuticals for management of T2DM. Overwhelming evidence has shown that the vast majority of *endogenously secreted* GLP-1 is rapidly degraded by endopeptidases, such as the DPP-IV enzyme, resulting in transient circulating levels of GLP-1 [see (74) for review]. Thus, under normal physiological conditions, paracrine-like signaling by GLP-1 plays a primary role in mediating intestinally-derived GLP-1 effects (67; 68; 74). In other words, evidence supports that GLP-1 secreted from intestinal L-cells acts locally on adjacent GLP-1R expressed on the peripheral terminals of vagal afferent fibers innervating the intestine to promote for insulin secretion and subsequent glycemic control, via a vago-vagal reflex (156) that stimulates the β -cells to secrete insulin (see (67) for review).

Direct evidence for the GLP-1 paracrine mode of action comes from rodent studies performing selective surgical ablation of the common hepatic branch (CHB) of the vagus nerve, the principal hepatoportal-innervating branch of the vagus (197). Rats with ablated CHB afferents continue to retain similar glycemic and food intake suppressive responses to endogenously produced or exogenously administered GLP-1, respectively, whereas rats with complete subdiaphragmatic vagal deafferentation (eliminating all vagal afferents) fail to show a GLP-1R-mediated incretin response and had a blunted suppression in glucose intake following exogenous systemic GLP-1 administration (197). Further support for an entero-vagal site of action by GLP-1 comes from the finding that inhibition of DPP-IV, specifically within the intestine and not in the general circulation, results in elevation of intestinal GLP-1 that can drive vagal afferent excitation and insulin secretion (194). Thus, the conservative

conclusion drawn from these findings is that vagal afferent communication is needed to mediate the glycemic and food intake inhibitory effects of systemic GLP-1 and is not dependent on the CHB, but rather neuronal signaling by the celiac and/or gastric vagal branches that innervate the GI tract.

II.B. Direct activation of GLP-1R expressed on pancreatic β -cells

The notion that paracrine-like signaling by intestinally derived GLP-1 is the primary physiological mode of action does not discount the potential secondary role of an endocrine-mediated mechanism that involves GLP-1 entering into circulation and having action on GLP-1R expressed either in the hepatoportal bed (98; 136; 137; 193) or directly on β -cells (101). Here, we discuss evidence for glycemic responses mediated by direct activation of GLP-1R expressed on pancreatic β -cells, as this effect undoubtedly occurs with pharmacological treatments targeting the GLP-1 system and/or with various gastric bypass surgeries (both discussed in further detail below).

Activation of GLP-1R expressed on pancreatic β -cells can result in coupling to $G\alpha_s$, $G\alpha_q$, $G\alpha_i$, and $G\alpha_o$ (8; 64; 128), stimulation of adenylate cyclase, elevated cAMP, and subsequent activation of protein kinase A and C (PKA; PKC), as well as phosphatidylinositol-3 kinase (PI3K) (58; 141). Interestingly, while the increase in adenylate cyclase and cAMP following β -cell GLP-1R activation is required for insulin secretion, activation of PKA does not appear to be a required component for this effect, although when activated, PKA signaling can potentiate insulin secretion (see (177) for review). The GLP-1-induced increase in cAMP augments glucose-stimulated insulin secretion by increasing the immediate fusion of insulin granules in the β -cell to the plasma membrane and ensuing insulin exocytosis. This process is mediated by both a PKA-dependent, but also a PKA-independent pathway that involves Epac (exchange protein activated by cAMP) (86; 177). In addition to promoting insulin exocytosis from the β -cell, intracellular signaling cascades following GLP-1R activation also stimulate insulin gene transcription and protein synthesis (44; 49; 54), putatively providing for a longer temporal control of postprandial insulin signaling. Finally, exciting complementary *in vivo* and *in vitro* evidence has pointed to a functional role for GLP-1R signaling in promoting β -cell proliferation and neogenesis (8; 120). Thus, continued exploration of the direct action of GLP-1 on β -cells is highly warranted as we continue to develop improved GLP-1-based pharmacotherapies for T2DM.

III. Central GLP-1 regulation of blood glucose and energy balance

III.A. CNS GLP-1 in control of glycemia

The CNS GLP-1 system plays a critical role in regulating glucose utilization in peripheral tissues (13; 65; 98) and is a potent stimulator of insulin secretion (98). Glucose intolerance has been reported in rats with chronic forebrain icv administration of the GLP-1R antagonist exendin-(9–39) or with virally-mediated knockdown of the GLP-1 precursor proglucagon (PPG) in the nucleus tractus solitarius (NTS) (13). Moreover, acute forebrain icv delivery of the GLP-1R antagonist exendin-(9–39) attenuates the utilization of glucose and increases glycogen synthesis in skeletal muscle (74). These findings indicate an endogenous role for the CNS GLP-1 system in glycemic control, yet the specific CNS GLP-1R-expressing nuclei

and mechanisms mediating central GLP-1's effects on glycemic regulation remain poorly understood.

The CNS GLP-1R-mediated effects on blood glucose regulation presumably involve modulation of the hypothalamo-pituitary-adrenocortical (HPA) axis (119) and/or autonomic pathways from the brain to the skeletal muscle and pancreas. Examples of similar hypothalamic and brainstem glucose-sensing pathways which modulate pancreatic insulin secretion and peripheral glucose utilization have been reviewed extensively elsewhere [see (188; 189; 199) for review]. GLP-1R activation can have divergent behavioral and physiological effects depending on the site of activation. Within the hypothalamus, activation of GLP-1R in the arcuate nucleus (ARH) suppresses hepatic glucose production and increases β -cell insulin secretion; however, no discernible effects on food intake have been reported (167). Conversely, activation of GLP-1R localized within the paraventricular nucleus of the hypothalamus (PVH) significantly reduces food intake but does not alter glucose homeostasis (167). The glycemic effects of hypothalamic GLP-1 are not limited to the ARH, as GLP-1R activation in the ventral medial hypothalamic nucleus (VMH) also modulates blood glucose (9).

Beyond the collective body of research examining hypothalamic GLP-1R-mediated effects on glycemia, however, there has been little investigation of non-hypothalamic GLP-1R-expressing nuclei in control of blood glucose. This is surprising considering that neural processing by the brainstem is sufficient to mediate the suppressive effects of GLP-1 on food intake and gastric emptying, as well as many of the energy expenditure parameters of GLP-1 (e.g. core temperature, heart rate) (70). Moreover, given the well-documented role of parasympathetic-mediated pathways that involves dorsal motor nucleus (DMV) vagal efferent signaling in control of glucose tolerance (188; 189; 199), that PPG-expressing neurons in the CNS are located almost exclusively in the NTS, and that GLP-1 signaling in the DMV excites pancreatic-projecting vagal motor neurons (195; 196), it stands to reason that hindbrain GLP-1R signaling may modulate blood glucose concentrations.

III.B. CNS GLP-1 in control of energy balance

Current FDA-approved GLP-1-based pharmacotherapies for T2DM treatment are either orally taken (DPP-IV inhibitors) or systemically injected (GLP-1R agonists), and undoubtedly both classes of drugs result in increased activation of GLP-1R expressed on the terminals of vagal afferent fibers innervating the GI tract and supporting organs of the alimentary canal [see (26; 67; 74) for review]. The role of vagal afferent signaling in mediating the food intake suppressive effects of intestinally-derived GLP-1 has also been extensively reviewed (60; 67; 74). Importantly, activation of central GLP-1Rs results in many of the same behavioral and physiological responses that are observed following peripheral GLP-1R ligand administration (e.g. inhibition of feeding, increased insulin secretion, reduced gastric emptying) (70; 97; 98; 169). When systemically administered, the GLP-1R agonists liraglutide and exendin-4 sufficiently penetrate the BBB and gain access to the brain in amounts sufficient to drive a physiological/behavioral response (81; 84), making it difficult to disentangle the effects originating in the periphery from those effects mediated by direct CNS activation. Instead, the best evidence supporting the relevance of the CNS

GLP-1 system in energy balance regulation are reports showing an endogenous role for the CNS GLP-1 system by: [1] chronic blockade of CNS GLP-1R by forebrain administration of the selective antagonist exendin-(9–39), which results in increased food intake and body weight (13; 117; 192), and [2] targeted viral knockdown of central GLP-1-producing PPG neurons, which results in hyperphagia and elevated weight gain (13). The current challenge of the field is to characterize the autonomic, endocrine, and behavioral responses mediated by individual GLP-1R-expressing nuclei. Indeed, while many CNS nuclei relevant for energy balance express GLP-1R, to date only a select few have been demonstrated to be physiologically required for the normal control of feeding (2; 42; 66; 169). Therefore, we will first highlight recent advances in our understanding of the brainstem, hypothalamic, and mesolimbic GLP-1R-mediated effects controlling for energy balance and subsequently focus on potential areas of new research with an eye towards hippocampal cognitive processes that involve GLP-1 signaling.

GLP-1 and hypothalamic/brainstem signaling—As briefly discussed above, examinations of hypothalamic GLP-1-mediated energy balance effects have been somewhat surprising. Despite the fact that GLP-1R are expressed on ARH proopiomelanocortin (POMC) neurons, which are required for the regulation of energy balance [see (35) for review], activation of ARH GLP-1R has no effect on food intake (167). Conversely, pharmacological activation of GLP-1R in the PVH, LH, DMH, or VMH suppresses food intake (115; 116; 169). Among these hypothalamic structures, however, to date only the LH GLP-1R populations have been shown to be physiologically relevant for the control of food intake, as blockade of LH GLP-1R produces a short-term increase in food intake (169). Further studies are therefore needed to determine whether blockade of GLP-1R in the PVH, DMH, and VMH can lead to an increase in food intake, to establish whether endogenous GLP-1 signaling in each of these sites are physiologically relevant for food intake regulation. Thus, although the hypothalamus is innervated abundantly by GLP-1 axonal projections from the NTS (102; 103; 154; 155), hypothalamic processing alone does not seem sufficient to mediate all of the feeding effects by the CNS GLP-1 system. Thus, a much broader exploration of GLP-1 neuroanatomy is needed with regard to energy balance control.

Despite the importance of forebrain GLP-1R signaling for food intake regulation (2; 39; 42; 97; 103; 116), hindbrain neural processing is sufficient to mediate the food intake-suppressive effects of peripherally or centrally administered GLP-1R agonists (70). Within the hindbrain, GLP-1R signaling in the medial NTS (mNTS) is physiologically relevant for the normal control of food intake (66). Furthermore, pharmacological activation of mNTS GLP-1R produces a robust suppression of food intake that can be sustained for over 24h (69; 203). Previous findings indicate that NTS GLP-1R-mediated suppression of food intake requires a cAMP/PKA-dependent activation of p44/42-MAPK and simultaneous suppression of adenosine monophosphate protein kinase (AMPK) (69). As the intake-suppressive effects of hindbrain GLP-1R activation are so robust and long-lasting, additional cAMP/PKA-dependent intracellular signaling pathways are undoubtedly required to mediate the suppression of intake by GLP-1R activation. Indeed, hindbrain GLP-1R-mediated suppression of food intake also involves a PI3K-PIP3-dependent translocation of Akt to the

plasma membrane and subsequent suppression of Akt phosphorylation (162). Together these intracellular signaling pathways interact to control for the feeding effects produced by mNTS GLP-1R activation, as a disruption of any one of these signaling pathways is sufficient to attenuate the food intake-suppressive effects produced by hindbrain GLP-1R activation. It is highly likely that these intracellular signals act together with additional downstream intracellular targets to modify transcriptional control, theoretically making a NTS GLP-1R-expressing neuron more sensitive to other anorectic signals processed within the NTS (see (61) for review).

GLP-1 and mesolimbic reward signaling—Drawing upon the appreciation that the excessive food intake that contributes to human obesity is not driven by metabolic need, a number of laboratories have made major advances in our understanding of the role that GLP-1 signaling in the nuclei of the mesolimbic reward system (MRS) has on energy balance control (2; 39; 42). This growing body of literature builds on the field's collective understanding of gustatory signaling from the oral cavity (primarily taste) and its synaptic connections to the MRS (138). Indeed, gustatory projections to limbic structures are responsible for engaging the nucleus accumbens (NAc) to modulate dopamine signaling (138). While these discoveries inform our thinking about feed-forward neural circuitry that promotes feeding, the contributions of antagonizing signals communicated to the MRS that accumulate as consumption of a meal progresses remain an extremely hot topic for investigation. The hypothesis that NTS GLP-1-producing PPG neurons function as a hub to connect within-meal GI-derived satiation signals with the hedonic/reward circuitry of the MRS provides a plausible mechanism to explain why the rewarding value of food is decreased in a sated state (6; 12; 27; 174; 175). To this end, recent complementary reports show that NTS PPG neurons project directly to the ventral tegmental area (VTA) (2) and NAc core and shell (2; 42). The connections to the VTA and NAc core were shown to be physiologically relevant for the control of palatable food intake, as GLP-1R blockade in either nucleus increased intake of palatable high-fat diet (HFD) (2). Given that dopaminergic projections from VTA to NAc are well-established and dopamine signaling in the MRS modulates food intake (93; 133), it is plausible that the reduction in food intake via GLP-1R activation in the VTA and NAc involves modulation of dopamine signaling and/or synthesis via presynaptic and/or post-synaptic mechanisms. In addition to dopamine, it has been proposed that opioid, GABA, and glutamate signaling in the MRS are also involved in regulating feeding (7; 94; 109; 110; 123; 133). At least for the VTA, recent behavioral and electrophysiological evidence suggests that GLP-1R are expressed on presynaptic glutamatergic axon terminals, whose cell bodies reside in other nuclei [e.g. NTS, prefrontal cortex, central nucleus of the amygdala (CeA)] (121). Activation of the VTA GLP-1R reduced intake of palatable high-fat diet primarily by reducing meal size, with minimal and inconsistent effects on meal frequency (121). The anorectic effects of intra-VTA GLP-1R activation were shown to be mediated in part by glutamatergic AMPA/kainate, but not NMDA, receptor signaling (121).

Beyond modulation of nutrient intake, emerging evidence suggests that satiation hormones, including GLP-1, may also regulate the reinforcing effects of alcohol intake and drugs of abuse [see (184) for review]. Thus, the GLP-1 system may serve as a novel target for drug

discovery programs aimed at developing pharmacotherapies for drug addiction (92). Given that the reinforcing effects of natural rewards (like palatable food) and drugs of abuse are regulated, in part, by the MRS (40; 133; 146; 170), it is possible that CNS GLP-1 signaling may also regulate drug taking and seeking. Recent studies demonstrate that peripheral administration of a GLP-1R agonist attenuates psychostimulant-induced conditioned place preference (CPP) and that these effects are associated with reduced extracellular dopamine levels in the NAc (47; 59). Unfortunately, it is not clear from these studies whether the effects of a peripherally administered GLP-1R agonist on psychostimulant-induced behavioral responses are due to direct stimulation of GLP-1R in the brain or through an indirect vagally-mediated mechanism that influences the MRS. Perhaps more importantly, as nausea and malaise-like symptoms are common adverse effects associated with high doses of peripherally administered GLP-1R agonists (84) (like the high doses used in the aforementioned CPP studies), it is impossible to disentangle reduced expression of CPP from place avoidance. Thus, further research is desperately needed to determine whether direct GLP-1 action in the MRS can modulate drug taking and seeking and do so in the absence of nausea/malaise (discussed in further detail below).

GLP-1 and hippocampal signaling—In addition to nuclei traditionally associated with homeostatic (e.g., ventromedial hypothalamus, caudal brainstem) and rewarding (e.g., nucleus accumbens, ventral tegmental area) aspects of feeding behavior, GLP-1Rs are also expressed in the hippocampus, a telencephalic structure linked with learning and memory function (118). In a series of papers, Greig and colleagues demonstrated that GLP-1 has neuroprotective effects against excitotoxic damage in hippocampal neurons (142), as well as against amyloid-beta peptide-induced neuronal death (143). Shortly thereafter, a pivotal paper from During et al. (46) demonstrated the functional relevance of hippocampal GLP-1R in learning and memory function. Pharmacological activation of CNS GLP-1R (via intracerebroventricular GLP-1 infusion) improved learning performance in a spatial learning test that is sensitive to hippocampal damage. Further evidence that hippocampal GLP-1R signaling improves learning and memory was provided by their results showing that GLP-1R deficient mice were impaired in a hippocampal-dependent contextual learning problem, and that viral vector-mediated up-regulation of GLP-1R gene expression targeted to the hippocampus markedly enhanced spatial learning performance relative to controls (46).

Having established a role for GLP-1 signaling in hippocampal-dependent learning, the challenge of the field is to elucidate the neurophysiological mechanisms through which GLP-1 exerts its memory promoting and neurotrophic effects on hippocampal neurons. GLP-1 has been shown to improve impairments in hippocampal synaptic plasticity (NMDA-mediated long-term potentiation) induced by pharmacological (198) or genetic (108) rodent models of Alzheimer's disease, as well as synaptic plasticity deficits induced by streptozotocin-induced diabetes (76). Given that the FDA-approved long-acting GLP-1R analogs, exendin-4 and liraglutide, are able to sufficiently penetrate the blood-brain barrier and act on CNS receptors (81; 87; 111), these neurotrophic properties may have clinical relevance for Alzheimer's and other dementias. In fact, chronic exendin-4 treatment restores learning and memory deficits in rodents induced by high fat diet feeding (56), or by intra-

hippocampal lipopolysaccharide administration (75). Similarly, Holscher and colleagues have demonstrated that chronic liraglutide treatment prevented memory impairments induced by a transgenic mouse model of Alzheimer's (113) and by diet-induced obesity (112). Thus, these GLP-1 analogs may prove to be clinically useful for dementia and other types of cognitive dysfunction that target the integrity of the hippocampus.

Given the robust influence of learning and memory processing on feeding behavior [see (34; 73; 80; 89; 190) for review], it is likely that the memory-promoting effects of hippocampal GLP-1R signaling are directly linked with the anorectic CNS actions of GLP-1. Neural processing in the hippocampus links contextual information with previous experience to guide behavior appropriately (17; 79; 91). This can influence feeding behavior not only based on external contextual cues (e.g., optimal foraging locations, feeding inhibition in predator environment), but also by integrating *internal* contextual cues with previous experience related to obtaining and/or consuming food. For example, rodents with selective hippocampal lesions cannot learn or retain a discrimination task in which different magnitudes of food deprivation serve as discriminative stimuli signaling the presence or absence of a palatable food reward (sucrose) (33). The internal context may be represented in the hippocampus via neuroendocrine signaling by GLP-1 and other peripherally-derived hormonal signals whose circulating levels vary with short- and long-term energy status. Indeed, in addition to GLP-1R, the hippocampus is densely populated with receptors for insulin, leptin, cholecystokinin, and ghrelin (32; 72; 176; 205). A series of recent studies show that neuronal processing in the ventral subregion of the hippocampus modulates appetitive behavior and food intake via signaling by both anorectic and orexigenic neuroendocrine ligands. The adipose tissue-derived hormone leptin acts on receptors in the ventral subregion of the hippocampus to suppress food intake and motivated responding for palatable food (runway performance for sucrose) (83). On the other hand, ghrelin receptor signaling in this region potently increases food intake, operant responding for sucrose, and meal initiation in response to environmental cues associated with food reward (82). While this hypothesis had not been directly tested, it may be the case that hippocampal GLP-1R signaling influences food seeking and consumption by promoting memory processes that link the internal energy status with previous experience to influence feeding behavior.

IV. GIP regulation of blood glucose and energy balance

Like GLP-1, GIP stimulates glucose-dependent insulin secretion, insulin transcription/translation, as well as β -cell growth and preservation of β -cell survival under normal physiological conditions [see (165) for review]. However, unlike GLP-1, there are few energy balance effects produced by GIP treatment alone and much of the beneficial glycemic effect of GIP signaling is impaired in states of chronic hyperglycemia (78). The latter fact has greatly precluded any significant pharmacological advancement for the GIP system as a primary treatment strategy for T2DM. It is also worth noting that there are many conflicting reports showing opposing metabolic benefits arising from activation or inhibition of GIP receptors. For example, GIP administration in hyperglycemic T2DM patients promotes glucagon secretion and worsens glucose tolerance (30), an effect contrary to GIP-mediated effects in euglycemic non-diabetic conditions (165). Yet, in mouse models, genetic deletion of the GIP receptor improves glucose tolerance and insulin sensitivity [see (26) for

review]. Thus, while emerging combination therapies involving GIP signaling are now being pursued as a potential treatment strategy for disruptions in glycemia and energy balance (165), the cautious view at this moment would be one that supports extensive further preclinical and clinical trials for GIP-based pharmacotherapy before considering any GIP-based compound as a viable treatment option for T2DM and/or obesity.

V. Amylin regulation of blood glucose and energy intake

The blood glucose-lowering actions of amylin receptor agonists [i.e. pramlintide, salmon calcitonin (sCT)] are among the most widely studied of amylin's multiple physiological functions [see (104; 107; 158; 159) for review]. Indeed, the amylin analog, pramlintide, is FDA-approved for the treatment of both type 1 and type 2 diabetes mellitus. In addition to the blood glucose regulatory effects, amylin signaling also suppresses food intake and body weight. Accordingly, the amylin system is a potentially attractive target for the pharmacological treatment of obesity due to its anorectic actions. The intake-inhibitory effects of amylin receptor agonists are mediated by direct action in the brain following stimulation of amylin receptors (104; 107; 158; 159). Amylin receptors are fairly unique in that they contain one of two splice variants of the calcitonin receptor (CTa/CTb; a G-protein coupled receptor) heterodimerized with one of the receptor activity modifying proteins (RAMP1, RAMP2 or RAMP3) [see (150; 157) for review]. Despite the fact that amylin readily crosses the BBB and gains access to much, if not all of the CNS (10; 11) where amylin receptors are widely distributed across the neuraxis (15; 16; 71; 178; 185), investigations of CNS nuclei and neuronal mechanisms mediating the anorectic effects of amylin signaling have been surprisingly restricted. A more comprehensive analysis of the mechanisms through which CNS amylin signaling reduces food intake is particularly warranted given recent interest in combining amylin with leptin receptor (LepRb) agonism, antagonists of the opioid system (e.g. naltrexone), and/or inhibitors of dopamine/norepinephrine reuptake (e.g. bupropion) for obesity treatment (28; 31; 104; 149; 160; 191).

The anorectic and body weight-suppressive effects of amylin receptor activation are mediated by a distributed network across the CNS that, to date, is known to involve processing by the area postrema (AP) (106; 125; 152), hypothalamus (148; 160), and VTA (122). Amylin action in the AP and VTA is physiologically relevant for the control of feeding and also potentially clinically relevant, as amylin receptor blockade in either site attenuates the intake suppressive effects of systemically injected amylin analogs (105; 122; 126; 153). From a therapeutic standpoint for future pharmacological treatment of obesity and potentially eating disorders (i.e. binge eating), the finding that blockade of amylin receptors in the VTA attenuates the intake-suppressive effects of a peripherally administered amylin analog suggests the potential for peripheral amylin analogs to affect VTA neural processing in humans. Given the critical role of the VTA in reward and motivational aspects of food intake control via dopaminergic inputs to the NAc (88; 133; 172), it is plausible that amylin action in the VTA controls for food intake by modulating the rewarding/motivational value of palatable food (122), as well as the ability of environmental food cues to trigger excessive food seeking and consumption. Such hypotheses require extensive further testing.

VI. Pathophysiological effects of amylin- and GLP-1-based pharmacotherapies

As highlighted above, there are tremendous opportunities for further pharmaceutical advancements in GLP-1- and amylin-based treatments for diabetes and obesity. Among the most notable goals of future GLP-1 and amylin pharmacotherapies should be the development of receptor ligands that exert enhanced suppression of blood glucose, food intake, and body weight but are able to achieve each of these effects with reduced incidence of adverse events. While it is true that FDA-approved GLP-1R (e.g. liraglutide and exenatide) and amylin receptor (e.g. pramlintide) ligands present negligible risk of life-threatening adverse events (e.g. cardiac abnormalities, depression, suicide ideation, renal failure) (20; 25; 127; 147; 164), neither class of drug is completely devoid of side effects that negatively impact quality of life and produce treatment attrition. Most notably, ~20–50% of T2DM patients prescribed GLP-1 medication experience nausea and/or vomiting, leading to discontinuation of drug treatment in ~6–10% and reduced dose tolerance in an additional ~15% (18; 24; 38; 77; 90). Similarly, patients prescribed the amylin analog pramlintide are conservatively estimated to be 1.8 times more likely to experience nausea compared to placebo treatment [see (182) for meta-review].

While the adverse effects of nausea and emesis are reported for both GLP-1- and amylin-based pharmacotherapies, it is surprising how uninvestigated these phenomenon are, as such staggering statistics limit the widespread use, efficacy, and potential future FDA approval of GLP-1R and amylin receptor ligands for use in obesity treatment. Perhaps a concern of researchers and pharmaceutical companies is that a portion of the food intake reduction produced by amylin and GLP-1R ligands is secondary to the induction of nausea; this concept is worthy of consideration, but is poorly understood. The lack of knowledge is partially attributable to the fact that unlike emesis (i.e., retching and vomiting), the subjective experience of nausea cannot be overtly measured in humans, which is underscored by the fact that available patient self-reporting tools for nausea have poor validity and reliability (22; 200). Another limitation related to the investigation of emesis/nausea/malaise by GLP-1R and amylin receptor ligands is that the vast majority of preclinical experimental investigations of these drugs have been conducted in rodents which lack the anatomy and physiology toretch and vomit [see (3) for review]. Importantly though, the absence of emesis by rodents does not indicate an absence of nausea/malaise; a similar scenario is observed in humans who experience nausea but do not vomit. Any attempt to quantify malaise by GLP-1 and amylin pharmacology in the rodent must be done so with the appreciation that the analyses are indirect semi-quantifiable measures of a subjective feeling and thus take advantage of alternative models: [1] taste reactivity (62; 63), the quantification of innate oral-motor facial responses indicative of aversion or acceptance; [2] conditioned taste avoidance (CTA), which is the avoidance of flavors or foods paired with illness (55) and; [3] pica, which is the consumption of nonnutritive substances (e.g., kaolin clay) in response to nausea-inducing agents (36; 37; 124), a behavior which may represent an innate adaptive response to reduce the adverse effects of toxins in the organism. While time-consuming, analyses that involve multiple measures of malaise done in concert with complementary experimentation in alternative animal models that do vomit (e.g. shrew

and ferret) will collectively deepen our understanding of the neurobiological mechanisms of emesis/nausea/malaise induced by GLP-1 and amylin-pharmacology. Indeed, in the case of GLP-1, we (84) and others (95; 166) have suggested that the field as a whole must utilize a multi-model approach to disentangle physiological (e.g. regulation of food intake and blood glucose) and pathophysiological (e.g. nausea/vomiting) effects produced by GLP-1 pharmacology.

While current amylin- and GLP-1-based pharmacotherapies are non-specific with regard to the cell populations that they act on, future research must invent and explore highly site-targeted pharmacotherapies for these systems if we are to achieve desired effects (i.e. food intake and blood glucose reductions) without producing maladaptive responses (i.e. nausea/vomiting). For example, in GLP-1R $-/-$ mice, re-expression of the GLP-1R exclusively on the pancreas is sufficient to restore much of the GLP-1-incretin effect (101). Thus, while vagal and CNS GLP-1R activation do participate in blood glucose regulation [see (65) for review], it is intriguing to consider the potential beneficial glycemic effects of a second generation of GLP-1R ligands that specifically acted on pancreatic β cell-expressing GLP-1R. Such a ligand would theoretically yield some glycemic improvements in T2DM patients with reduced incidence of adverse events. A similar strategy could also be applied to the GLP-1- and amylin-mediated mechanisms controlling for food intake and body weight. As discussed above, BBB-penetrance is undoubtedly occurring for current amylin and GLP-1 ligands, and the physiological and behavioral effects produced by the activation of a given nucleus can be quite distinct from the responses yielded by receptor activation at another CNS structure. For example, selective VTA or NAc core GLP-1R activation reduces palatable food intake without producing any measured malaise in rodents (absence of CTA and pica) (2; 39; 42). While it would be useful to confirm that VTA/NAc core GLP-1R activation does not produce emesis using a mammalian model capable of vomiting, the aforementioned complementary set of data identify these GLP-1R-expressing mesolimbic nuclei as clinically attractive from the standpoint of creating a second-generation GLP-1 ligand to reduce food intake without producing nausea/malaise. Such a targeted ligand is greatly needed, as current GLP-1R ligands are gaining access to the whole CNS, where GLP-1R activation in nuclei such as the NTS or CeA will produce a CTA and/or pica response along with varying degrees of food intake suppression (84; 97). As detailed in Table 1, many GLP-1R-expressing nuclei can modulate food intake when activated by GLP-1 or GLP-1R agonists. The task at hand for the field is to systematically evaluate the mechanisms by which food intake is suppressed by GLP-1R signaling in each of these nuclei, and whether any adverse events (e.g. nausea) might be contributing to the feeding effects.

VII. A role for incretin and amylin signaling in gastric bypass-mediated improvements in glycemia and body weight

Bariatric surgery for the purposes of weight loss is currently among the top elective procedures across the U.S. These procedures, which alter the GI tract to either limit nutrient exposure to absorptive sites within the proximal gut (e.g., Roux-en-Y Gastric Bypass; RYGB), and/or limit the volume of food voluntarily ingested by the patient (e.g., gastric lap

banding, sleeve gastrectomy), have all been largely successful in promoting sustained weight loss in obese individuals, and certainly serve as the standard in weight loss treatment strategies when compared to broadly disappointing results from most FDA-approved pharmacotherapies (134).

RYGB (especially laparoscopic RYGB) is still considered the gold standard for weight loss surgery, although these procedures are not without their limitations. Approximately 20–30% of RYGB patients fail to reach the typical postoperative weight loss and/or begin to regain large amounts of weight within the first year (85; 144; 168; 186). Despite this minority of the patient population, the vast majority of obese individuals undergoing bariatric surgeries achieve tremendous and unmatched metabolic and health outcome improvements. Perhaps the most remarkable positive health outcome from RYGB is that obese patients with T2DM see profound improvements in glycemic control, often within a matter of days (23; 144; 161; 183). Such strong metabolic improvements in RYGB patients have prompted considerable clinical and basic science research focused on elucidating the hormonal and metabolic mechanisms that may mediate these effects. Current thinking has shifted away from the original idea that metabolic improvements following RYGB were principally due to restricted absorption of nutrients, to new efforts aimed at unlocking what impact gastric bypass has on the neuroendocrine controls that govern food intake and glycemic regulation (161; 187; 204). Prevalent among this emerging research is the idea that GI-derived incretin hormones and amylin serve an integral role in enhancing satiation, as well as regulating blood glucose in postoperative gastric bypass patients (99). Of similar interest are investigations that examine alterations in vagally-mediated gut-to-brain communication following RYGB and what role, if any, these altered vagal communications play in weight loss and glycemic control (180).

VII.A. The vagus nerve and RYGB

The role of vagal afferent innervation within the GI tract and subsequent transmission of sensory signals regulating food intake are well-established (19; 173). Removing vagal input to the hindbrain via chemical or surgical ablation of selective branches can significantly diminish the satiating potency of numerous hormones and signaling molecules controlling energy balance. Similarly, diet-induced obesity may result in reduced sensitivity to satiation signals [e.g., (41)], and increase expression of orexigenic vagal signaling (140), either of which could lead to or exacerbate hyperphagia and obesity. Despite such well-known involvement in energy balance, a paucity of reports exist which address whether vago-vagal signaling alterations contribute to metabolic improvements following RYGB. During this procedure it is likely that a significant number of vagal fibers are resected, which may impact satiation signaling, as well as hormonal release. Recent work by Peters et al. suggests that the effects of vagotomy involve a considerable degree of plasticity within both vagal afferent and synaptic transmission of vagal fibers to the NTS (145). These experiments highlight a potential system of transient withdrawal and remodeling of the vagal network which may serve to explain some of the neuroendocrine effects of gastric bypass. Surgical resection of the CHB of the vagus, a primarily sensory branch with afferent innervation of the liver, proximal duodenum, and pancreas, has little effect on intake following RYGB in the rat (180). However, these results do not preclude involvement of more distal branches/

sites of vagal innervation such as the celiac branch, which due to anatomical re-positioning of the roux and common limbs, could receive more nutrient and/or vagal sensory activation than in normal physiology.

VII.B. Incretin hormones and amylin following RYGB: Why is RYGB so successful?

While many hormones and gut peptides have alterations in their secretion, plasma concentrations, and post-prandial responsiveness following RYGB, for the purposes of brevity we will focus here on GLP-1, PYY3-36, and amylin, as major neuroendocrine signals accompanying both the weight loss and normalization of glycemia following RYGB. Numerous preclinical and clinical studies are in agreement that RYGB patients show a rapid and sustained increase in postprandial GLP-1 secretion that is greater in magnitude than that seen in either obese non-surgical controls or obese controls undergoing other gastrointestinal surgery (i.e. gastric banding) (99; 135; 171). Similar results have been shown with PYY3-36 (132; 171). Collectively, these findings are consistent with the notion that the rapid and sustained postprandial GLP-1 and PYY3-36 secretion observed following RYGB could result from a greater concentration of nutrients being exposed to the L cells in the jejunum and ileum now that a large portion of the stomach and all of the duodenum have been bypassed. An additional, non-exclusive idea is that specific enteroendocrine cells, like the L-cells, adapt in response to the anatomical reorganization of RYGB, resulting in enhanced proliferation and expression of the cell-type. Indeed, there are reports showing an up-regulation of immunoreactivity for GLP-1- and PYY-producing cells in the intestine following RYGB (131; 134).

It would be useful to elucidate how enhanced secretion/satiating ability of GLP-1 and PYY3-36 could impact obesity treatment as a welcome alternative to radical bariatric procedures. Recent data from Reidelberger et al. showed that when exendin-4 and PYY3-36 were co-administered to DIO rats using multiple dosing/administration strategies, including doses consistent with plasma observations in RYGB patients, food intake- and body weight-suppressive effects became increasingly complex in interpretation due to the apparent tolerance of dosing, tachyphylaxis, and counteraction by competing orexigenic mechanisms which together mitigate the suppressive effects of exendin-4 and PYY3-36 (151). Thus it is clear that simply “boosting the signal” of distal-gut satiation/incretin hormones via RYGB, and the exact mechanisms that account for this increase in postprandial GLP-1 and PYY secretion following RYGB, warrants further investigation. The consequences are just beginning to be examined in both humans and animals (96; 100; 129; 130; 161; 187; 204).

Among the most emergent potential players in the peripheral signaling enhancement following RYGB is that of amylin. Postprandial increases in amylin have been reported following RYGB (181); however, over time (and unlike GLP-1 and PYY3-36) amylin levels tend to decrease or show little change (21). As highlighted above, it is also likely that amylin and GLP-1 may act through distinctive, and largely complementary mechanisms to produce ameliorative effects on weight loss and maintenance, as well as restoration of glucose homeostasis following RYGB [for review, see (158)].

Summary and Future Directions for Therapeutic Advancement

The opportunity for advancement in pharmaceutical treatments of obesity and T2DM continues to expand with the new discoveries in the physiological and pathophysiological effects mediated by the amylin and GLP-1 systems. As detailed above, further exploration of the cellular/molecular signaling pathways of GLP-1R and amylin receptor activation will likely provide new opportunities for future pharmacotherapies targeting signaling pathways that interact with the GLP-1 and amylin systems. The development of second-generation receptor agonists for the GLP-1R and the amylin receptor that can selectively target specific nuclei in the CNS may also provide an opportunity to treat diseases without producing undesirable adverse events (e.g. nausea). Recent discoveries of GLP-1 and amylin action in the mesolimbic reward system in control of energy balance is also exciting when considering the possible implications for pharmacological targeting of these systems as a means to treat other diseases like drug addiction and depression that are associated with disrupted perception of reward and pleasure. Finally, given the redundancy of neuroendocrine systems involved in the regulation of energy balance, as well as in the maintenance of blood glucose concentrations, it seems logical that a realistic and sustainable pharmacological approach to the treatment of either obesity or T2DM will require a cocktail of new, highly specific, drugs that act in concert to produce an enhanced suppression of food intake and/or glycemic concentration. As discussed in this review, combination drug therapies would be well-suited to include amylin- and/or GLP-1-based ligands.

Acknowledgments

We thank James Valmer and Louis T. Dalton for critical reading of the manuscript. This work was supported in part by NIH grants: DK085435 and DK096139 (MRH); DK097147 (SEK).

References

1. Akesson B, Panagiotidis G, Westermark P, Lundquist I. Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. *Regul Pept.* 2003; 111:55–60. [PubMed: 12609749]
2. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. *Endocrinology.* 2012; 153:647–58. [PubMed: 22128031]
3. Andrews PL, Horn CC. Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases. *Auton Neurosci.* 2006; 125:100–15. [PubMed: 16556512]
4. Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? *J Clin Endocrinol Metab.* 2010; 95:2367–75. [PubMed: 20194711]
5. Aston-Mourney K, Hull RL, Zraika S, Udayasankar J, Subramanian SL, Kahn SE. Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. *Diabetologia.* 2011; 54:1756–65. [PubMed: 21484213]
6. Babcock AM, Livovsky M, Avery DD. Cholecystokinin and bombesin suppress operant responding for food reward. *Pharmacol Biochem Behav.* 1985; 22:893–5. [PubMed: 4011643]
7. Badiani A, Leone P, Noel MB, Stewart J. Ventral tegmental area opioid mechanisms and modulation of ingestive behavior. *Brain Res.* 1995; 670:264–76. [PubMed: 7743190]
8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology.* 2007; 132:2131–57. [PubMed: 17498508]

9. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. 2007; 132:2131–57. [PubMed: 17498508]
10. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. *Peptides*. 1998; 19:883–9. [PubMed: 9663454]
11. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. Permeability of the blood-brain barrier to amylin. *Life Sci*. 1995; 57:1993–2001. [PubMed: 7475950]
12. Barbano MF, Le Saux M, Cador M. Involvement of dopamine and opioids in the motivation to eat: influence of palatability, homeostatic state, and behavioral paradigms. *Psychopharmacology (Berl)*. 2009; 203:475–87. [PubMed: 19015837]
13. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. *J Neurosci*. 2011; 31:3904–13. [PubMed: 21389245]
14. Beales IL, Calam J. Regulation of amylin release from cultured rabbit gastric fundic mucosal cells. *BMC physiology*. 2003; 3:13. [PubMed: 14572315]
15. Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. *Molecular pharmacology*. 1993; 44:493–7. [PubMed: 8396712]
16. Becskei C, Riediger T, Zund D, Wookey P, Lutz TA. Immunohistochemical mapping of calcitonin receptors in the adult rat brain. *Brain Res*. 2004; 1030:221–33. [PubMed: 15571671]
17. Benoit SC, Davis JF, Davidson TL. Learned and cognitive controls of food intake. *Brain Res*. 2010; 1350:71–6. [PubMed: 20561510]
18. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet*. 2010; 376:431–9. [PubMed: 20580422]
19. Berthoud HR. The vagus nerve, food intake and obesity. *Regulatory peptides*. 2008; 149:15–25. [PubMed: 18482776]
20. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. *Diabetes Obes Metab*. 2006; 8:436–47. [PubMed: 16776751]
21. Bose M, Machineni S, Olivan B, Teixeira J, McGinty JJ, et al. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. *Obesity*. 2010; 18:1085–91. [PubMed: 20057364]
22. Brearley SG, Clements CV, Molassiotis A. A review of patient self-report tools for chemotherapy-induced nausea and vomiting. *Support Care Cancer*. 2008; 16:1213–29. [PubMed: 18551323]
23. Buchwald H, Estok R, Fahrenbach K, Banel D, Jensen MD, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med*. 2009; 122:248–56. e5. [PubMed: 19272486]
24. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care*. 2004; 27:2628–35. [PubMed: 15504997]
25. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009; 374:39–47. [PubMed: 19515413]
26. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. *Cell Metab*. 2013; 17:819–37. [PubMed: 23684623]
27. Carr KD, Simon EJ. Potentiation of reward by hunger is opioid mediated. *Brain Res*. 1984; 297:369–73. [PubMed: 6326944]
28. Chan JL, Roth JD, Weyer C. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*. 2009; 57:777–83. [PubMed: 20029268]
29. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. *Nat Rev Endocrinol*. 2012; 8:228–36. [PubMed: 22064493]

30. Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. *Diabetes*. 2009; 58:1342–9. [PubMed: 19276444]
31. Clapper JR, Athanacio J, Wittmer C, Griffin PS, D'Souza L, et al. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. *Eur J Pharmacol*. 2013; 698:292–8. [PubMed: 23178527]
32. Craft S, Asthana S, Newcomer J, Wilkinson C, Matos I, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. *Arch Gen Psychiatry*. 1999; 56:1135–40. [PubMed: 10591291]
33. Davidson TL, Kanoski SE, Chan K, Clegg DJ, Benoit SC, Jarrard LE. Hippocampal lesions impair retention of discriminative responding based on energy state cues. *Behav Neurosci*. 2010; 124:97–105. [PubMed: 20141284]
34. Davidson TL, Kanoski SE, Walls EK, Jarrard LE. Memory inhibition and energy regulation. *Physiol Behav*. 2005; 86:731–46. [PubMed: 16263144]
35. De Jonghe BC, Hayes MR, Bence KK. Melanocortin control of energy balance: evidence from rodent models. *Cell Mol Life Sci*. 2011; 68:2569–88. [PubMed: 21553232]
36. De Jonghe BC, Horn CC. Chemotherapy-induced pica and anorexia are reduced by common hepatic branch vagotomy in the rat. *Am J Physiol Regul Integr Comp Physiol*. 2008; 294:R756–65. [PubMed: 18184757]
37. De Jonghe BC, Lawler MP, Horn CC, Tordoff MG. Pica as an adaptive response: Kaolin consumption helps rats recover from chemotherapy-induced illness. *Physiol Behav*. 2009; 97:87–90. [PubMed: 19419663]
38. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2005; 28:1092–100. [PubMed: 15855572]
39. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. *J Neurosci*. 2012:32.
40. DiLeone RJ, Taylor JR, Picciotto MR. The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction. *Nat Neurosci*. 2012; 15:1330–5. [PubMed: 23007187]
41. Donovan MJ, Paulino G, Raybould HE. CCK(1) receptor is essential for normal meal patterning in mice fed high fat diet. *Physiology & behavior*. 2007; 92:969–74. [PubMed: 18023701]
42. Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-like Peptide 1 receptors in nucleus accumbens affect food intake. *J Neurosci*. 2011; 31:14453–7. [PubMed: 21994361]
43. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. *Diabetes*. 2013; 62:3316–23. [PubMed: 23818527]
44. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *Proc Natl Acad Sci U S A*. 1987; 84:3434–8. [PubMed: 3033647]
45. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. *J Clin Endocrinol Metab*. 2011; 96:2027–31. [PubMed: 21734003]
46. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.[see comment]. *Nat Med*. 2003; 9:1173–9. [PubMed: 12925848]
47. Egecioglu E, Engel JA, Jerlhag E. The glucagon-like Peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. *PLoS One*. 2013; 8:e69010. [PubMed: 23874851]
48. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma Insulin Response to Oral and Intravenous Glucose Administration. *J Clin Endocrinol Metab*. 1964; 24:1076–82. [PubMed: 14228531]
49. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. *Endocrinology*. 1992; 130:159–66. [PubMed: 1309325]

50. Finkelstein EA, Brown DS, Wragge LA, Allaire BT, Hoerger TJ. Individual and aggregate years-of-life-lost associated with overweight and obesity. *Obesity* (Silver Spring). 2010; 18:333–9. [PubMed: 19680230]
51. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. *Health Aff (Millwood)*. 2009; 28:w822–31. [PubMed: 19635784]
52. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. *JAMA*. 2010; 303:235–41. [PubMed: 20071471]
53. Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. *Transplantation*. 2008; 86:36–45. [PubMed: 18622276]
54. Fu Z, Gilbert ER, Liu D. Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes. *Curr Diabetes Rev*. 2012
55. Garcia J, Kimeldorf DJ, Koelling RA. Conditioned aversion to saccharin resulting from exposure to gamma radiation. *Science*. 1955; 122:157–8. [PubMed: 14396377]
56. Gault VA, Porter WD, Platt PR, Holscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. *Int J Obes (Lond)*. 2010; 34:1341–4. [PubMed: 20351729]
57. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, et al. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). *Biochem Biophys Res Commun*. 1998; 250:271–7. [PubMed: 9753619]
58. Gomez E, Pritchard C, Herbert TP. cAMP-dependent protein kinase and Ca²⁺ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. *J Biol Chem*. 2002; 277:48146–51. [PubMed: 12364324]
59. Graham DL, Erreger K, Galli A, Stanwood GD. GLP-1 analog attenuates cocaine reward. *Mol Psychiatry*. 2013; 18:961–2. [PubMed: 23089631]
60. Gribble FM. The gut endocrine system as a coordinator of postprandial nutrient homeostasis. *Proc Nutr Soc*. 2012; 71:456–62. [PubMed: 22906726]
61. Grill HJ, Hayes MR. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. *Cell Metab*. 2012; 16:296–309. [PubMed: 22902836]
62. Grill HJ, Norgren R. The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. *Brain Res*. 1978; 143:263–79. [PubMed: 630409]
63. Grill HJ, Norgren R. The taste reactivity test. II. Mimetic responses to gustatory stimuli in chronic thalamic and chronic decerebrate rats. *Brain Res*. 1978; 143:281–97. [PubMed: 630410]
64. Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, Langel U. Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. *Biochim Biophys Acta*. 2001; 1546:79–86. [PubMed: 11257510]
65. Hayes MR. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. *Physiol Behav*. 2012; 106:413–6. [PubMed: 22366059]
66. Hayes MR, Bradley L, Grill HJ. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. *Endocrinology*. 2009; 150:2654–9. [PubMed: 19264875]
67. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. *Physiol Behav*. 2010; 100:503–10. [PubMed: 20226203]
68. Hayes MR, Kanoski SE, De Jonghe BC, Lechner TM, Alhadeff AL, et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. *Am J Physiol Regul Integr Comp Physiol*. 2011
69. Hayes MR, Lechner TM, Zhao S, Lee GS, Chowansky A, et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. *Cell Metab*. 2011; 13:320–30. [PubMed: 21356521]
70. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. *Endocrinology*. 2008; 149:4059–68. [PubMed: 18420740]

71. Hilton JM, Chai SY, Sexton PM. In vitro autoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain. *Neuroscience*. 1995; 69:1223–37. [PubMed: 8848109]
72. Hokfelt T, Cortes R, Schalling M, Ceccatelli S, Peltö-Huikko M, et al. Distribution patterns of CCK and CCK mRNA in some neuronal and non-neuronal tissues. *Neuropeptides*. 1991; 19(Suppl):31–43. [PubMed: 1881531]
73. Holland PC, Petrovich GD. A neural systems analysis of the potentiation of feeding by conditioned stimuli. *Physiol Behav*. 2005; 86:747–61. [PubMed: 16256152]
74. Holst JJ. The physiology of glucagon-like peptide 1. *Physiol Rev*. 2007; 87:1409–39. [PubMed: 17928588]
75. Huang HJ, Chen YH, Liang KC, Jheng YS, Zhao JJ, et al. Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. *PLoS One*. 2012; 7:e39656. [PubMed: 22844396]
76. Iwai T, Suzuki M, Kobayashi K, Mori K, Mogi Y, Oka J. The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. *Neuroscience research*. 2009; 64:67–74. [PubMed: 19321133]
77. John LE, Kane MP, Busch RS, Hamilton RA. Expanded Use of Exenatide in the Management of Type 2 Diabetes. *Diabetes Spectrum*. 2007; 20:59–63.
78. Jones IR, Owens DR, Vora J, Luzio SD, Hayes TM. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus. *Diabetes research and clinical practice*. 1989; 7:263–9. [PubMed: 2693029]
79. Kanoski SE. Cognitive and neuronal systems underlying obesity. *Physiol Behav*. 2012; 106:337–44. [PubMed: 22266286]
80. Kanoski SE, Davidson TL. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. *Physiol Behav*. 2011; 103:59–68. [PubMed: 21167850]
81. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4. *Endocrinology*. 2011; 152:3103–12. [PubMed: 21693680]
82. Kanoski SE, Fortin SM, Ricks KM, Grill HJ. Ghrelin Signaling in the Ventral Hippocampus Stimulates Learned and Motivational Aspects of Feeding via PI3K-Akt Signaling. *Biol Psychiatry*. 2013; 73:915–23. [PubMed: 22884970]
83. Kanoski SE, Hayes MR, Greenwald HS, Fortin SM, Gianessi CA, et al. Hippocampal leptin signaling reduces food intake and modulates food-related memory processing. *Neuropsychopharmacology*. 2011; 36:1859–70. [PubMed: 21544068]
84. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. *Neuropharmacology*. 2012; 62:1916–27. [PubMed: 22227019]
85. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. *Ann Surg*. 2008; 247:401–7. [PubMed: 18376181]
86. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, et al. Critical role of cAMP-GEFII–Rim2 complex in incretin-potentiated insulin secretion. *J Biol Chem*. 2001; 276:46046–53. [PubMed: 11598134]
87. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. *Int J Obes Relat Metab Disord*. 2003; 27:313–8. [PubMed: 12629557]
88. Kelley AE. Functional specificity of ventral striatal compartments in appetitive behaviors. *Ann N Y Acad Sci*. 1999; 877:71–90. [PubMed: 10415644]
89. Kelley AE. Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. *Neuroscience & Biobehavioral Reviews*. 2004; 27:765–76. [PubMed: 15019426]
90. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care*. 2005; 28:1083–91. [PubMed: 15855571]

91. Kennedy PJ, Shapiro ML. Retrieving memories via internal context requires the hippocampus. *Journal of Neuroscience*. 2004; 24:6979–85. [PubMed: 15295033]
92. Kenny PJ. Common cellular and molecular mechanisms in obesity and drug addiction. *Nat Rev Neurosci*. 2011; 12:638–51. [PubMed: 22011680]
93. Kenny PJ. Reward mechanisms in obesity: new insights and future directions. *Neuron*. 2011; 69:664–79. [PubMed: 21338878]
94. Khaimova E, Kandov Y, Israel Y, Cataldo G, Hadjimarkou MM, Bodnar RJ. Opioid receptor subtype antagonists differentially alter GABA agonist-induced feeding elicited from either the nucleus accumbens shell or ventral tegmental area regions in rats. *Brain Res*. 2004; 1026:284–94. [PubMed: 15488491]
95. Khanna G, O'Dorisio SM, Menda Y, Kirby P, Kao S, Sato Y. Gastroenteropancreatic neuroendocrine tumors in children and young adults. *Pediatric radiology*. 2008; 38:251–9. quiz 358–9. [PubMed: 17906857]
96. Kindel TL, Yoder SM, Seeley RJ, D'Alessio DA, Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. *J Gastrointest Surg*. 2009; 13:1762–72. [PubMed: 19488823]
97. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. *J Neurosci*. 2002; 22:10470–6. [PubMed: 12451146]
98. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. *J Clin Invest*. 2005; 115:3554–63. [PubMed: 16322793]
99. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. *Surg Obes Relat Dis*. 2007; 3:597–601. [PubMed: 17936091]
100. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. *Obesity (Silver Spring)*. 2006; 14:1553–61. [PubMed: 17030966]
101. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. *J Clin Invest*. 2012; 122:388–402. [PubMed: 22182839]
102. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. *Neuroscience*. 1997; 77:257–70. [PubMed: 9044391]
103. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. *Endocrinology*. 1997; 138:4445–55. [PubMed: 9322962]
104. Lutz TA. The role of amylin in the control of energy homeostasis. *Am J Physiol Regul Integr Comp Physiol*. 2010; 298:R1475–84. [PubMed: 20357016]
105. Lutz TA. Control of energy homeostasis by amylin. *Cell Mol Life Sci*. 2012; 69:1947–65. [PubMed: 22193913]
106. Lutz TA, Senn M, Althaus J, Del Prete E, Ehrensperger F, Scharer E. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. *Peptides*. 1998; 19:309–17. [PubMed: 9493863]
107. Lutz TA, Tschudy S, Rushing PA, Scharer E. Amylin receptors mediate the anorectic action of salmon calcitonin (sCT). *Peptides*. 2000; 21:233–8. [PubMed: 10764950]
108. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1(9–36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. *J Neurosci*. 2012; 32:13701–8. [PubMed: 23035082]
109. MacDonald AF, Billington CJ, Levine AS. Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat. *Am J Physiol Regul Integr Comp Physiol*. 2003; 285:R999–R1004. [PubMed: 12907414]

110. MacDonald AF, Billington CJ, Levine AS. Alterations in food intake by opioid and dopamine signaling pathways between the ventral tegmental area and the shell of the nucleus accumbens. *Brain Res.* 2004; 1018:78–85. [PubMed: 15262208]
111. McClean, P.; Kung, K.; McCurtin, R.; Gault, V.; Holscher, C. Novel GLP-1 analogues cross the blood brain barrier: A link between diabetes and Alzheimer's disease. *Proc. Society for Neuroscience: Annual Meeting*; Chicago, IL. 2009;
112. McClean PL, Gault VA, Harriott P, Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. *Eur J Pharmacol.* 2010; 630:158–62. [PubMed: 20035739]
113. McClean PL, Parthasarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. *J Neurosci.* 2011; 31:6587–94. [PubMed: 21525299]
114. McIntyre N, Holdsworth CD, Turner DS. New Interpretation of Oral Glucose Tolerance. *Lancet.* 1964; 2:20–1. [PubMed: 14149200]
115. McMahon LR, Wellman PJ. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7–36) amide. *Pharmacol Biochem Behav.* 1997; 58:673–7. [PubMed: 9329057]
116. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7–36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. *Am J Physiol.* 1998; 274:R23–9. [PubMed: 9458894]
117. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat. *Endocrinology.* 1999; 140:244–50. [PubMed: 9886831]
118. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. *J Comp Neurol.* 1999; 403:261–80. [PubMed: 9886047]
119. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. *J Comp Neurol.* 1999; 403:261–80. [PubMed: 9886047]
120. Miao XY, Liu Y, Li CL, Gu ZY, Liu P, et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. *Peptides.* 2012
121. Miettlicki-Baase EG, Ortinski PI, Rupprecht LE, Olivos DR, Alhadeff AL, et al. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. *Am J Physiol Endocrinol Metab.* 2013
122. Miettlicki-Baase EG, Rupprecht LE, Olivos DR, Zimmer DJ, Alter MD, et al. Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake. *Neuropsychopharmacology.* 2013; 38:1685–97. [PubMed: 23474592]
123. Miner P, Borkuhova Y, Shimonova L, Khaimov A, Bodnar RJ. GABA-A and GABA-B receptors mediate feeding elicited by the GABA-B agonist baclofen in the ventral tegmental area and nucleus accumbens shell in rats: reciprocal and regional interactions. *Brain Res.* 2010; 1355:86–96. [PubMed: 20696149]
124. Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK. Poison induced pica in rats. *Physiol Behav.* 1976; 17:691–7. [PubMed: 1034944]
125. Mollet A, Gilg S, Riediger T, Lutz TA. Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. *Physiology & behavior.* 2004; 81:149–55. [PubMed: 15059694]
126. Mollet A, Gilg S, Riediger T, Lutz TA. Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. *Physiol Behav.* 2004; 81:149–55. [PubMed: 15059694]
127. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. *Clin Ther.* 2009; 31:2472–88. [PubMed: 20109994]
128. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein

- kinase pathways in Chinese hamster ovary cells. *Endocrinology*. 1999; 140:1132–40. [PubMed: 10067836]
129. Morinigo R, Lacy AM, Casamitjana R, Delgado S, Gomis R, Vidal J. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. *Obes Surg*. 2006; 16:1594–601. [PubMed: 17217635]
 130. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. *J Clin Endocrinol Metab*. 2006; 91:1735–40. [PubMed: 16478824]
 131. Mumphrey MB, Patterson LM, Zheng H, Berthoud HR. Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*. 2013; 25:e70–9. [PubMed: 23095091]
 132. Nannipieri M, Baldi S, Mari A, Colligiani D, Guarino D, et al. Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: Mechanisms of Diabetes Remission and Role of Gut Hormones. *J Clin Endocrinol Metab*. 2013
 133. Narayanan NS, Guarnieri DJ, DiLeone RJ. Metabolic hormones, dopamine circuits, and feeding. *Front Neuroendocrinol*. 2010; 31:104–12. [PubMed: 19836414]
 134. Neff KJ, le Roux CW. Bariatric surgery: a best practice article. *Journal of clinical pathology*. 2013; 66:90–8. [PubMed: 23172552]
 135. Neff KJ, O'Shea D, le Roux CW. Glucagon like peptide-1 (GLP-1) dynamics following bariatric surgery: a Signpost to a new frontier. *Curr Diabetes Rev*. 2013; 9:93–101. [PubMed: 23230996]
 136. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. *J Auton Nerv Syst*. 2000; 80:14–21. [PubMed: 10742535]
 137. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Nijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. *J Auton Nerv Syst*. 1996; 61:149–54. [PubMed: 8946334]
 138. Norgren R, Hajnal A, Mungarnde SS. Gustatory reward and the nucleus accumbens. *Physiol Behav*. 2006; 89:531–5. [PubMed: 16822531]
 139. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. *J Clin Invest*. 1990; 85:973–6. [PubMed: 2179271]
 140. Paulino G, Barbier de la Serre C, Knotts TA, Oort PJ, Newman JW, et al. Increased expression of receptors for orexigenic factors in nodose ganglion of diet-induced obese rats. *Am J Physiol Endocrinol Metab*. 2009; 296:E898–903. [PubMed: 19190260]
 141. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. *Eur J Endocrinol*. 2000; 143:717–25. [PubMed: 11124853]
 142. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. *J Pharmacol Exp Ther*. 2002; 302:881–8. [PubMed: 12183643]
 143. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. *Journal of neuroscience research*. 2003; 72:603–12. [PubMed: 12749025]
 144. Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. *Ann Surg*. 2009; 250:234–41. [PubMed: 19638921]
 145. Peters JH, Gallaher ZR, Ryu V, Czaja K. Withdrawal and restoration of central vagal afferents within the dorsal vagal complex following subdiaphragmatic vagotomy. *The Journal of comparative neurology*. 2013; 521:3584–99. [PubMed: 23749657]

146. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? *Neurosci Biobehav Rev*. 2006; 30:215–38. [PubMed: 16099045]
147. Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. *Ther Clin Risk Manag*. 2010; 6:401–11. [PubMed: 20856686]
148. Potes CS, Lutz TA, Riediger T. Identification of central projections from amylin-activated neurons to the lateral hypothalamus. *Brain Res*. 2010; 1334:31–44. [PubMed: 20382134]
149. Potes CS, Turek VF, Cole RL, Vu C, Roland BL, et al. Noradrenergic neurons of the area postrema mediate amylin's hypophagic action. *Am J Physiol Regul Integr Comp Physiol*. 2010; 299:R623–31. [PubMed: 20554938]
150. Qi T, Ly K, Poyner DR, Christopoulos G, Sexton PM, Hay DL. Structure-function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors. *Peptides*. 2011; 32:1060–7. [PubMed: 21402116]
151. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM. Effects of exendin-4 alone and with peptide YY(3–36) on food intake and body weight in diet-induced obese rats. *Obesity*. 2011; 19:121–7. [PubMed: 20559304]
152. Riediger T, Schmid HA, Lutz TA, Simon E. Amylin and glucose co-activate area postrema neurons of the rat. *Neuroscience letters*. 2002; 328:121–4. [PubMed: 12133570]
153. Riediger T, Zuend D, Becskei C, Lutz TA. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. *Am J Physiol Regul Integr Comp Physiol*. 2004; 286:R114–22. [PubMed: 12958059]
154. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. *Am J Physiol*. 1999; 277:R582–90. [PubMed: 10444567]
155. Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. *Brain Res*. 2010; 1350:18–34. [PubMed: 20353764]
156. Rinaman L, Card JP, Schwaber JS, Miselis RR. Ultrastructural demonstration of a gastric monosynaptic vagal circuit in the nucleus of the solitary tract in rat. *J Neurosci*. 1989; 9:1985–96. [PubMed: 2723763]
157. Roth JD. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. *Current opinion in endocrinology, diabetes, and obesity*. 2013; 20:8–13.
158. Roth JD, Erickson MR, Chen S, Parkes DG. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. *Br J Pharmacol*. 2012; 166:121–36. [PubMed: 21671898]
159. Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. *Archives of neurology*. 2009; 66:306–10. [PubMed: 19273748]
160. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. *Proc Natl Acad Sci U S A*. 2008; 105:7257–62. [PubMed: 18458326]
161. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. *Annu Rev Med*. 2010; 61:393–411. [PubMed: 20059345]
162. Rupprecht LE, Mietlicki-Baase EG, Zimmer DJ, McGrath LE, Olivos DR, Hayes MR. Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt. *Am J Physiol Endocrinol Metab*. 2013; 305:E751–9. [PubMed: 23900416]
163. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. *Endocrinology*. 2001; 142:5035. [PubMed: 11606473]

164. Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. *Int J Clin Pract.* 2010; 64:1402–14. [PubMed: 20716148]
165. Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. *Nat Rev Endocrinol.* 2013
166. Sandoval D, Barrera JG, Stefater MA, Sisley S, Woods SC, et al. The anorectic effect of GLP-1 in rats is nutrient dependent. *PLoS One.* 2012; 7:e51870. [PubMed: 23284795]
167. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate GLP-1 receptors regulate glucose homeostasis but not food intake. *Diabetes.* 2008
168. Sarwer DB, Faulconbridge LF, Steffen KJ, Roerig JL, Mitchell JE. The Management of Mood Disorders with Anti-depressant Medications After Bariatric Surgery. *Current Psychiatry.* 2010 (In Press).
169. Schick RR, Zimmermann JP, vom Walde T, Schusdziaira V. Peptides that regulate food intake: glucagon-like peptide 1-(7–36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. *Am J Physiol Regul Integr Comp Physiol.* 2003; 284:R1427–35. [PubMed: 12776726]
170. Schmidt HD, Anderson SM, Famous KR, Kumaresan V, Pierce RC. Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking. *Eur J Pharmacol.* 2005; 526:65–76. [PubMed: 16321382]
171. Scholtz S, Miras AD, Chhina N, Prechtel CG, Sleeth ML, et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. *Gut.* 2013
172. Schultz W. Predictive reward signal of dopamine neurons. *J Neurophysiol.* 1998; 80:1–27. [PubMed: 9658025]
173. Schwartz GJ, Zeltser LM. Functional organization of neuronal and humoral signals regulating feeding behavior. *Annual review of nutrition.* 2013; 33:1–21.
174. Sclafani A. Oral and postoral determinants of food reward. *Physiol Behav.* 2004; 81:773–9. [PubMed: 15234183]
175. Sclafani A, Ackroff K. The relationship between food reward and satiation revisited. *Physiol Behav.* 2004; 82:89–95. [PubMed: 15234596]
176. Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, et al. Leptin targets in the mouse brain. *J Comp Neurol.* 2009; 514:518–32. [PubMed: 19350671]
177. Seino S, Takahashi H, Fujimoto W, Shibasaki T. Roles of cAMP signalling in insulin granule exocytosis. *Diabetes Obes Metab.* 2009; 11(Suppl 4):180–8. [PubMed: 19817800]
178. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. *Neuroscience.* 1994; 62:553–67. [PubMed: 7830897]
179. Sherwin R, Jastreboff AM. Year in diabetes 2012: The diabetes tsunami. *J Clin Endocrinol Metab.* 2012; 97:4293–301. [PubMed: 23185035]
180. Shin AC, Zheng H, Berthoud HR. Vagal innervation of the hepatic portal vein and liver is not necessary for Roux-en-Y gastric bypass surgery-induced hypophagia, weight loss, and hypermetabolism. *Ann Surg.* 2012; 255:294–301. [PubMed: 22202582]
181. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. *Endocrinology.* 2010; 151:1588–97. [PubMed: 20179262]
182. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab.* 2011; 13:169–80. [PubMed: 21199269]
183. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med.* 2004; 351:2683–93. [PubMed: 15616203]
184. Skibicka KP. The central GLP-1: implications for food and drug reward. *Front Neurosci.* 2013; 7:181. [PubMed: 24133407]
185. Skofitsch G, Wimalawansa SJ, Jacobowitz DM, Gubisch W. Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat

- central nervous system. *Canadian journal of physiology and pharmacology*. 1995; 73:945–56. [PubMed: 8846435]
186. Strain GW, Gagner M, Pomp A, Dakin G, Inabnet WB, et al. Comparison of weight loss and body composition changes with four surgical procedures. *Surg Obes Relat Dis*. 2009; 5:582–7. [PubMed: 19560983]
 187. Stylopoulos N, Hoppin AG, Kaplan LM. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. *Obesity (Silver Spring)*. 2009; 17:1839–47. [PubMed: 19556976]
 188. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. *Diabetes Obes Metab*. 2011; 13(Suppl 1):82–8. [PubMed: 21824260]
 189. Thorens B. Sensing of glucose in the brain. *Handbook of experimental pharmacology*. 2012; 209:277–94. [PubMed: 22249819]
 190. Tracy AL, Jarrard LE, Davidson TL. The hippocampus and motivation revisited: appetite and activity. *Behav Brain Res*. 2001; 127:13–23. [PubMed: 11718882]
 191. Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. *Obesity (Silver Spring)*. 2010; 18:21–6. [PubMed: 19543217]
 192. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature*. 1996; 379:69–72. [PubMed: 8538742]
 193. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. *Endocrinology*. 2007; 148:4965–73. [PubMed: 17584962]
 194. Waget A, Cabou C, Masseboeuf M, Cattani P, Armanet M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. *Endocrinology*. 2011; 152:3018–29. [PubMed: 21673098]
 195. Wan S, Browning KN, Travagli RA. Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons. *Peptides*. 2007; 28:2184–91. [PubMed: 17889966]
 196. Wan S, Coleman FH, Travagli RA. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. *Am J Physiol Gastrointest Liver Physiol*. 2007; 292:G1474–82. [PubMed: 17322063]
 197. Wang FB, Powley TL. Vagal innervation of intestines: afferent pathways mapped with new en bloc horseradish peroxidase adaptation. *Cell Tissue Res*. 2007; 329:221–30. [PubMed: 17453246]
 198. Wang XH, Li L, Holscher C, Pan YF, Chen XR, Qi JS. Val8-glucagon-like peptide-1 protects against Abeta1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. *Neuroscience*. 2010; 170:1239–48. [PubMed: 20727946]
 199. Watts AG, Donovan CM. Sweet talk in the brain: glucosensing, neural networks, and hypoglycemic counterregulation. *Front Neuroendocrinol*. 2010; 31:32–43. [PubMed: 19836412]
 200. Wood JM, Chapman K, Eilers J. Tools for assessing nausea, vomiting, and retching. *Cancer Nurs*. 2011; 34:E14–24. [PubMed: 21188798]
 201. Young A. Inhibition of gastric emptying. *Adv Pharmacol*. 2005; 52:99–121. [PubMed: 16492543]
 202. Young A. Inhibition of glucagon secretion. *Adv Pharmacol*. 2005; 52:151–71. [PubMed: 16492545]
 203. Zhao S, Kanoski SE, Yan J, Grill HJ, Hayes MR. Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. *Int J Obes (Lond)*. 2012
 204. Zheng H, Shin AC, Lenard NR, Townsend RL, Patterson LM, et al. Meal patterns, satiety, and food choice in a rat model of Roux-en-Y gastric bypass surgery. *Am J Physiol Regul Integr Comp Physiol*. 2009; 297:R1273–82. [PubMed: 19726714]
 205. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin receptor mRNA in the rat and the mouse brain. *J Comp Neurol*. 2006; 494:528–48. [PubMed: 16320257]

Figure 1.

The mechanisms by which GLP-1, GIP, and amylin regulate food intake and blood glucose involve complex, overlapping, and redundant endocrine and neuronal pathways. Solid lines indicate a direct mode of action, whereas dotted lines indicate control through an indirect mechanism. Lines with dual inhibition and arrow signs indicate evidence for both directions of effects. Supporting literature for the pathways illustrated here that is not highlighted elsewhere in this review can be found here: (1; 4; 5; 14; 43; 53; 57; 163; 201; 202).

Table 1

Abbreviation list: NTS (nucleus tractus solitarius); AP (area postrema); DMV (dorsal motor nucleus of the vagus); PVH (paraventricular nucleus of the hypothalamus); ARH (arcuate nucleus of the hypothalamus); LH (lateral nucleus of the hypothalamus); DMH (dorsal medial nucleus of the hypothalamus); VMH (ventral medial nucleus of the hypothalamus); VTA (ventral tegmental area); NAcC (nucleus accumbens core); NAcSh (nucleus accumbens shell); CeA (central nucleus of the amygdala); HPF (hippocampal formation); CTA (conditioned taste avoidance).

Nucleus	Evidence for Food Intake Control	Evidence for Glycemic Control	Nausea/Malaise Evidence
NTS	Physiological and Pharmacological Evidence	Unknown	Pica
AP	No Direct Pharmacological Evidence	Unknown	Unknown
DMV	No Pharmacological Evidence	Unknown/Possible	Unknown
PVH	Pharmacological Evidence	No Pharmacological Evidence	No CTA
ARH	No Pharmacological Evidence	Pharmacological Evidence	Unknown
LH	Physiological and Pharmacological Evidence	Unknown	Unknown
DMH	Pharmacological Evidence	Unknown	Unknown
VMH	Pharmacological Evidence	Unknown	Unknown
VTA	Physiological and Pharmacological Evidence	Unknown	No CTA or Pica
NAcC	Physiological and Pharmacological Evidence	Unknown	No CTA or Pica
NAcSh	Pharmacological Evidence	Unknown	No CTA or Pica
CeA	No Pharmacological Evidence	Unknown	CTA
HPF	Unknown/Possible	Unknown	Unknown
Nodose (Vagal Afferent)	Physiological and Pharmacological Evidence	Physiological and Pharmacological Evidence	Not Required for Pica